Geoffrey Wade Smith - Jan 26, 2023 Form 3 Insider Report for Orchestra BioMed Holdings, Inc. (OBIO)

Role
Director
Signature
Geoffrey W. Smith
Stock symbol
OBIO
Transactions as of
Jan 26, 2023
Transactions value $
$0
Form type
3
Date filed
1/30/2023, 02:05 PM
Next filing
May 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OBIO Warrants (Right to Buy) Jan 26, 2023 Common Stock 15K $11.50 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received prior to the business combination of Orchestra BioMed, Inc. ("Orchestra") with Health Sciences Acquisitions Corporation 2 ("HSAC2") pursuant to which, among other things, HSAC2 domesticated as a Delaware corporation and changed its name to "Orchestra BioMed Holdings, Inc." ("New Orchestra") and, promptly thereafter, HSAC Olympus Merger Sub, Inc. merged with and into Orchestra with Orchestra surviving the merger as a wholly owned subsidiary of New Orchestra.
F2 Fifty percent (50%) of these warrants will become exercisable 24 months after completion of the business combination and the remaining fifty percent (50%) of these warrants will become exercisable 36 months after completion of the business combination, in each case subject to the reporting person's continued service with New Orchestra or one of its subsidiaries through such date.

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney